drugset / Trial / NCT01311739

Oral Cyanocobalamin (Eligen B12) Bioavailability Study

NCT01311739

Completed 20 enrolled Emisphere Technologies, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess and compare the pharmacokinetics (PK) of cyanocobalamin after the oral administration of Eligen® B12 (cyanocobalamin/SNAC), oral cyanocobalamin alone (commercially-available formulation) and cyanocobalamin administered intravenously (IV) (also a commercially-available formulation) to healthy male subjects under fasting conditions. The safety and tolerability of oral Eligen® B12 (cyanocobalamin/SNAC) versus oral cyanocobalamin alone and versus IV cyanocobalamin are also assessed.

Timeline

Start
2008-05
Primary completion
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin B12 Other / unclassified 1 mg Oral
Subject Vitamin B12 Other / unclassified 5 mg Oral
Subject Vitamin B12 Other / unclassified 10 mg Oral

Indications

No indication recorded.